A Study to Assess the Safety of TPM502 in Adults With Celiac Disease

Inclusion Criteria:

• Availability of a documented biopsy-confirmed diagnosis of CeD OR documented tissuetransglutaminase >10x ULN and documented positive IgA anti-endomysial antibody (EMA)at time of CeD diagnosis (as per local guidelines)

• Serum anti-tissue transglutaminase 2 immunoglobin A antibodies within normal range (i.e., <15 U/mL) at screening

• Serum IL-2 levels (AUC1-6h) above a pre-defined threshold following the GC atscreening

• Patients must have been on GFD for ≥ 6 months

• Patients must have well-controlled CeD, defined as mild or with no ongoing signs orsymptoms felt to be related to active CeD, as per investigator's assessment

• HLA-DQ2.5 positive

Exclusion Criteria:

• Known or suspected refractory CeD (refractory CeD type I or II)

• Known intolerable symptoms following previous GCs, as per investigator's assessment

• HLA DQ8 positive

• Any active gastrointestinal disease such as gastroesophageal reflux disease,esophagitis or peptic ulcer, microscopic colitis, or irritable bowel syndrome, whichin the opinion of the investigator might interfere with the assessment of thesymptoms related to CeD

• Known history of or active Crohn's disease, ulcerative colitis, or ulcerativejejunitis

• Known wheat allergy

• Known hypersensitivity to i.v. iron preparations or any other excipients present inthe reconstituted TPM502 or placebo